In our second annual report, we evaluate the industry’s performance — financial, financing and transaction activity — and provide not-to-be-missed insights from leading medtech organizations.

How can you manage your company through recession and position yourself for growth? After interviewing thousands of life sciences executives, we identified overarching themes.

This document discusses the creative models to overcome immediate operational challenges and foster long-term growth in the biotechnology sector.

Ernst & Young, along with the Economic Intelligence Unit, interviewed executives from leading global life sciences companies to learn how they remain competent.

As Washington changes direction, many question whether reform policies will present new opportunities or risks for the pharma, biotech, and medtech sectors.

Despite the global economic crisis, the Swiss biotechnology sector is booming. In fact, companies have already announced plans to create hundreds of jobs this year.

Read our report to find out which 10 business risks are affecting the pharmaceutical industry worldwide.

In this edition of bio*link, we summarize common accounting issues related to clinical activities and provide examples of good internal controls.

This report is an update to the previously released Pulse of the industry: US medical technology report 2008.

This publication discusses implications of the new accounting rules, which apply to transactions, closing dates on or after 1 January 2009 for calendar year companies.